Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

Technology appraisal guidance
Reference number: TA428
Published: 11 January 2017
Last updated: 12 September 2017

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 232 KB)

Published:

11 January 2017

Final appraisal determination

Final appraisal determination
Final appraisal determination document (PDF 531 KB)

Published:

02 December 2016
Committee papers (PDF 4.01 MB)

Published:

02 December 2016
Committee papers Slides (PDF 807 KB)

Published:

02 December 2016

Draft guidance

Draft guidance
Appraisal consultation document (PDF 341 KB)

Published:

04 October 2016
Committee papers (PDF 12.56 MB)

Published:

04 October 2016
Committee papers Committee meeting presentation slides (PDF 577 KB)

Published:

04 October 2016

Invitation to participate

Final matrix (PDF 178 KB)

Published:

05 January 2016
NICE's response to comments on the draft scope and provisional matrix (PDF 271 KB)

Published:

03 February 2016
Final scope (PDF 112 KB)

Published:

04 May 2016

Draft scope documents

Draft scope (pre-referral) (PDF 118 KB)

Published:

27 November 2015
Provisional matrix (pre-referral) (PDF 176 KB)

Published:

27 November 2015